Clinical trial · Interventional
Combined Therapy for Hepatocellular Carcinoma >3-<5 cm
Combined Therapy With Conventional Trans-arterial Chemoembolization (cTACE) and Microwave Ablation (MWA) for Hepatocellular Carcinoma >3-<5 cm
NCT04721470CI-TRIAL-00049571completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare the safety and efficacy of combined therapy with conventional transarterial chemoembolization (cTACE) + microwave ablation (MWA) versus only TACE or MWA for treatment of hepatocellular carcinoma (HCC) \>3-\<5 cm.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Combined therapy | Procedure | — | UNRESOLVED |
| Microwave ablation | Procedure | — | UNRESOLVED |
| Transarterial chemoembolization | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Combined therapy
- description
- Patients undergoing combined therapy
- interventionNames
- Procedure: Combined therapy
- type
- ACTIVE_COMPARATOR
- label
- Transarterial chemoembolization
- description
- Patients undergoing Transarterial chemoembolization
- interventionNames
- Procedure: Transarterial chemoembolization
- type
- ACTIVE_COMPARATOR
- label
- Microwave ablation
- description
- Patients undergoing Microwave ablation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Solitary HCC \>3-\<5 cm 2. Absence of extra-hepatic metastases 3. Absence of a history of encephalopathy or refractory ascites 4. Child-Pugh class A or B cirrhosis. Exclusion Criteria: 1. Poor patient compliance 2. Child-Pugh class C cirrhosis 3. Severe coagulation disorders 4. Portal vein thrombosis 5. Renal impairment (6) previous local ablation therapy of HCC
References
Publications (1)
- DERIVEDZaitoun MMA, Elsayed SB, Zaitoun NA, Soliman RK, Elmokadem AH, Farag AA, Amer M, Hendi AM, Mahmoud NEM, Salah El Deen D, Alsowey AM, Shahin S, Basha MAA. Combined therapy with conventional trans-arterial chemoembolization (cTACE) and microwave ablation (MWA) for hepatocellular carcinoma >3-<5 cm. Int J Hyperthermia. 2021;38(1):248-256. doi: 10.1080/02656736.2021.1887941. PMID 33615957